Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Glenn MacNichol

Interventional Pain Medicine Rocky Mount, NC Medical Doctor

NPI 1245297811 CMS profile 282938

110 Patrick Ct, Rocky Mount, NC 27804

Open in the dashboard

General payments

$4,105

318 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Glenn MacNichol of Rocky Mount, NC is reported in the CMS Open Payments database as having received $4,105 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $521 35
2024 General $532 44
2023 General $642 51
2022 General $657 52
2021 General $608 47
2020 General $537 40
2019 General $607 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glenn MacNichol
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Glenn MacNichol were reported at $521. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Glenn MacNichol Interventional Pain Medicine median Middle half National median
2019 $607 $684 $216–$2,079 $163
2020 $537 $382 $122–$1,109 $114
2021 $608 $552 $167–$1,554 $132
2022 $657 $605 $187–$1,924 $149
2023 $642 $671 $195–$1,915 $160
2024 $532 $684 $206–$1,837 $164
2025 $521 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,475 170 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $447 26 payments
  3. Collegium Pharmaceutical, Inc. $389 19 payments
  4. IBSA Pharma Inc. $333 17 payments
  5. Scilex Pharmaceuticals Inc. $193 12 payments
  6. Nevro Corp. $157 10 payments
  7. Radius Health, Inc. $134 6 payments
  8. Pfizer Inc. $133 8 payments
  9. Globus Medical, Inc. $81 4 payments
  10. Masimo Corporation $71 4 payments
  11. Other $693 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,081 317 payments
  2. Entertainment $24 1 payment
Products named General payments · program years 2019–2025
  1. PROCLAIM $632 76 payments
  2. RELISTOR $404 24 payments
  3. Licart $333 17 payments
  4. Tirosint Endocrinology $312 16 payments
  5. Proclaim Family of SCS IPGs $294 34 payments
  6. BELBUCA $284 14 payments
  7. Proclaim IPG $225 24 payments
  8. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $138 9 payments
  9. TIROSINT Endocrinology $131 7 payments
  10. Flector $123 6 payments
  11. Other $1,965 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,732

Median for Anesthesiology: 322

Drug cost

$205,966

Median for Anesthesiology: $8,738

Branded share of claims

37.4%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 37 $91,228
Xtampza Er Oxycodone Myristate Brand 64 $36,315
Linzess Linaclotide Brand 11 $11,657
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 427 $11,062
Buprenorphine Generic 41 $9,199
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 266 $9,010
Gabapentin Generic 480 $7,019
Pregabalin Generic 199 $5,070
Nucynta Er Tapentadol Hcl Brand 11 $5,041
Diclofenac Sodium Generic 60 $2,737

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$390,793

Of which drugs: $32,007

Medicare patients

569

Average age 72

Services billed

10,269

350 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Chronic kidney disease 36%
Ischemic heart disease 32%
Depression 30%
COPD 23%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 24 1,504 $20,685
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 274 1,432 $7,922
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 103 862 $663
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 206 980 $278
Injection, ketorolac tromethamine, per 15 mg J1885 Office 36 476 $226
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 21 220 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $83
$83 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $42
$42 37 —
Tirosint
  • IBSA Pharma Inc. $36
$36 — —
Licart
  • IBSA Pharma Inc. $36
$36 — —
MOVANTIK
  • Valinor Pharma, LLC $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record